Hodgkin Lymphoma Treatment Market
Hodgkin Lymphoma Treatment Market Size, Share & Trends Analysis Report, By Treatment Modality (Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy, Others), By Drug Class (Cytotoxic Drugs, ADC, Immune Checkpoint Inhibitors, Corticosteroids), By Route of Administration (IV, Oral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Forecast Period (2026–2035)
Industry Overview
Hodgkin lymphoma treatment market was valued at $5.2 billion in 2025 and is projected to reach $10.1 billion by 2035, growing at a CAGR of 6.8% during 2026–2035. The market growth is driven by increasing cancer incidence, advancements in immunotherapy, and rising healthcare expenditure globally. According to the World Health Organization, cancer remains one of the leading causes of death worldwide. The International Agency for Research on Cancer projects global cancer cases to reach over 35 million by 2050. This rising disease burden significantly boosts demand for effective lymphoma treatments. This growing patient pool directly translates into higher demand for effective treatments, including chemotherapy, immunotherapy, and targeted therapies for Hodgkin lymphoma.
Major end-use sectors include hospitals, oncology centres, and speciality clinics, where intravenous therapies dominate. Increasing adoption of advanced biologics such as checkpoint inhibitors and antibody-drug conjugates is transforming treatment protocols and improving survival outcomes, thereby driving market expansion.
Market Dynamics
Rising Cancer Burden and Immunotherapy Adoption Driving Market Growth
The increasing global cancer burden is a key driver of the Hodgkin lymphoma treatment market. According to the World Health Organization, cancer incidence is steadily rising due to ageing populations and lifestyle-related risk factors. Additionally, the IQVIA highlights that global spending on oncology medicines continues to grow annually, driven by high-value biologics and precision therapies. The adoption of immunotherapy has significantly improved treatment outcomes. Drugs such as Pembrolizumab and Nivolumab have demonstrated strong efficacy in relapsed Hodgkin lymphoma cases. In 2025–2026, pharmaceutical companies are focusing on expanding indications and combination therapies to enhance treatment effectiveness. Increasing regulatory approvals and clinical advancements are further accelerating market growth.
High Treatment Costs and Limited Patient Pool Restraining Market Expansion
Despite strong growth potential, the market faces challenges related to high treatment costs and a limited patient population. Advanced therapies such as immunotherapy and ADCs are expensive, limiting accessibility in developing regions. According to the Organisation for Economic Co-operation and Development, healthcare expenditure disparities across countries significantly impact access to advanced cancer treatments. Supply chain complexities and stringent regulatory approvals also create barriers for new entrants. Additionally, chemotherapy drugs face pricing pressure due to generic competition. Companies are responding through cost optimization strategies, biosimilar development, and partnerships to expand access while maintaining profitability.
Market Segmentation
- Based on the treatment modality, the market is segmented into chemotherapy, immunotherapy, radiation therapy, targeted therapy, and others.
- Based on the drug class, the market is segmented into cytotoxic drugs, antibody-drug conjugates (ADC), immune checkpoint inhibitors, and corticosteroids.
- Based on the route of administration, the market is segmented into intravenous (IV) and oral.
- Based on the distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
Immune Checkpoint Inhibitors Segment Leads the Market
The immune checkpoint inhibitors segment dominates the market due to high adoption and strong clinical outcomes. These therapies enhance the body’s immune response against cancer cells, improving survival rates in relapsed cases. Pharmaceutical companies such as Merck & Co., Inc. and Bristol-Myers Squibb Company have expanded their immunotherapy portfolios in recent years through label expansions and clinical trials, strengthening their market presence. High pricing and increasing global adoption contribute significantly to revenue generation.
Antibody-Drug Conjugates Segment to Record Strong Growth
The antibody-drug conjugates (ADC) segment is expected to witness the fastest growth during the forecast period. These targeted therapies deliver cytotoxic agents directly to cancer cells, minimizing damage to healthy tissues. Innovations in drug delivery and increasing R&D investments are driving this segment. Companies such as Takeda Pharmaceutical Company Limited and Pfizer Inc. are investing heavily in ADC development and commercialization, accelerating segment growth.
Regional Outlook
The global hodgkin lymphoma treatment market is geographically segmented into North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa and Latin America).
United States Leads the Market
The United States continues to dominate the Hodgkin lymphoma treatment market due to its strong oncology ecosystem and rapid adoption of innovative biologics. According to the U.S. Food and Drug Administration, 50 novel drugs were approved in 2024, with oncology remaining a leading therapeutic area, accelerating access to advanced treatments. Additionally, the Centres for Medicare & Medicaid Services estimates U.S. healthcare expenditure exceeded $5.2 trillion in 2024. The country also leads in clinical trials and immunotherapy adoption, supported by favourable reimbursement systems and the strong presence of key pharmaceutical companies. These factors collectively reinforce its leadership in the global market.
China to Record Strong Growth
China is projected to witness strong growth in the Hodgkin lymphoma treatment market due to rising cancer incidence and expanding healthcare investments. According to the International Agency for Research on Cancer (latest available data), China reported over 4.8 million new cancer cases annually, accounting for the largest global share. The Chinese government continues to strengthen healthcare access through national insurance expansion and oncology-focused reforms. Increasing domestic drug manufacturing, faster regulatory approvals, and growing adoption of advanced therapies are improving treatment accessibility. Rising healthcare expenditure and awareness programs are further supporting sustained market growth.
Competitive Landscape
The Hodgkin lymphoma treatment market is highly competitive, with key companies such as Merck & Co., Inc., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Pfizer Inc., and F. Hoffmann-La Roche Ltd focusing on innovation, strategic collaborations, and geographic expansion. Additionally, dominate the market through strong product portfolios and continuous R&D investments.
Recent Developments
- In March 2026, Bristol-Myers Squibb Company announced expanded approvals of Opdivo (nivolumab) across the U.S. and European Union for multiple classical Hodgkin lymphoma indications, including first-line and relapsed/refractory settings. The approvals strengthen immunotherapy adoption and redefine standard-of-care treatment approaches in Hodgkin lymphoma.
- In February 2025, Pfizer Inc. announced that the U.S. Food and Drug Administration approved ADCETRIS (brentuximab vedotin) as part of combination therapy for lymphoma indications. ADCETRIS is a CD30-directed antibody-drug conjugate used in the treatment of classical Hodgkin lymphoma, reinforcing Pfizer’s position in targeted oncology therapies.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global Hodgkin lymphoma treatment market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Hodgkin Lymphoma Treatment Market Sales Analysis – Treatment Modality | Drug Class | Route of Administration | Distribution Channel ($ Million)
- Hodgkin Lymphoma Treatment Market Sales Performance of Top Countries
1.1 Research Methodology
- Primary Research Approach
- Secondary Research Approach
1.2 Market Snapshot
- Market Overview and Insights
2.1 Scope of the Study
2.2 Analyst Insight & Current Market Trends
2.2.1 Key Hodgkin Lymphoma Treatment Market Trends
2.2.2 Market Recommendations
2.3 Porter's Five Forces Analysis for the Hodgkin Lymphoma Treatment Market
2.3.1 Competitive Rivalry
2.3.2 Threat of New Entrants
2.3.3 Bargaining Power of Suppliers
2.3.4 Bargaining Power of Buyers
2.3.5 Threat of Substitutes
- Market Determinants
3.1 Market Drivers
3.1.1 Drivers For Global Hodgkin Lymphoma Treatment Market: Impact Analysis
3.2 Market Pain Points and Challenges
3.2.1 Restraints For Global Hodgkin Lymphoma Treatment Market: Impact Analysis
3.3 Market Opportunities
3.3.1 Opportunities For Global Hodgkin Lymphoma Treatment Market: Impact Analysis
- Competitive Landscape
4.1 Competitive Dashboard – Hodgkin Lymphoma Treatment Market Revenue and Share by Manufacturers
- Hodgkin Lymphoma Treatment Product Comparison Analysis
- Top Market Player Ranking Matrix
4.2 Company Analysis
4.2.1 Bristol-Myers Squibb Company
4.2.1.1 Overview
4.2.1.2 Product Portfolio
4.2.1.3 Financial Analysis
4.2.1.4 SWOT Analysis
4.2.1.5 Business Strategy
4.2.2 F. Hoffmann-La Roche Ltd
4.2.2.1 Overview
4.2.2.2 Product Portfolio
4.2.2.3 Financial Analysis
4.2.2.4 SWOT Analysis
4.2.2.5 Business Strategy
4.2.3 Merck & Co., Inc.
4.2.3.1 Overview
4.2.3.2 Product Portfolio
4.2.3.3 Financial Analysis
4.2.3.4 SWOT Analysis
4.2.3.5 Business Strategy
4.2.4 Pfizer
4.2.4.1 Overview
4.2.4.2 Product Portfolio
4.2.4.3 Financial Analysis
4.2.4.4 SWOT Analysis
4.2.4.5 Business Strategy
4.2.5 Takeda Pharmaceutical Company Limited
4.2.5.1 Overview
4.2.5.2 Product Portfolio
4.2.5.3 Financial Analysis
4.2.5.4 SWOT Analysis
4.2.5.5 Business Strategy
4.3 Top Winning Strategies by Market Players
4.3.1 Merger and Acquisition
4.3.2 Product Launch
4.3.3 Partnership and Collaboration
- Global Hodgkin Lymphoma Treatment Market Sales Analysis by Treatment Modality ($ Million)
5.1 Chemotherapy
5.2 Immunotherapy
5.3 Radiation Therapy
5.4 Targeted Therapy
5.5 Others
- Global Hodgkin Lymphoma Treatment Market Sales Analysis by Drug Class ($ Million)
6.1 Cytotoxic Drugs (Chemotherapy)
6.2 Antibody-Drug Conjugates (ADC)
6.3 Immune Checkpoint Inhibitors
6.4 Corticosteroids (supportive, minor share)
- Global Hodgkin Lymphoma Treatment Market Sales Analysis by Route of Administration ($ Million)
7.1 Intravenous (IV)
7.2 Oral
- Global Hodgkin Lymphoma Treatment Market Sales Analysis by Distribution Channel ($ Million)
8.1 Hospital Pharmacies
8.2 Retail Pharmacies
8.3 Online Pharmacies
- Regional Analysis
9.1 North American Hodgkin Lymphoma Treatment Market Sales Analysis – Treatment Modality | Drug Class | Route of Administration | Distribution Channel ($ Million)
9.1.1 United States
9.1.2 Canada
9.2 European Hodgkin Lymphoma Treatment Market Sales Analysis – Treatment Modality | Drug Class | Route of Administration | Distribution Channel ($ Million)
9.2.1 UK
9.2.2 Germany
9.2.3 Italy
9.2.4 Spain
9.2.5 France
9.2.6 Russia
9.2.7 Rest of Europe
9.3 Asia-Pacific Hodgkin Lymphoma Treatment Market Sales Analysis – Treatment Modality | Drug Class | Route of Administration | Distribution Channel ($ Million)
9.3.1 China
9.3.2 Japan
9.3.3 South Korea
9.3.4 India
9.3.5 Australia & New Zealand
9.3.6 ASEAN Countries
9.3.7 Rest of Asia-Pacific
9.4 Rest of the World Hodgkin Lymphoma Treatment Market Sales Analysis – Treatment Modality | Drug Class | Route of Administration | Distribution Channel ($ Million)
9.4.1 Latin America
9.4.2 Middle East and Africa
- Company Profiles
10.1 Accord Healthcare Limited
10.1.1 Quick Facts
10.1.2 Company Overview
10.1.3 Product Portfolio
10.1.4 Business Strategies
10.2 Baxter International Inc.
10.2.1 Quick Facts
10.2.2 Company Overview
10.2.3 Product Portfolio
10.2.4 Business Strategies
10.3 Bristol-Myers Squibb Company
10.3.1 Quick Facts
10.3.2 Company Overview
10.3.3 Product Portfolio
10.3.4 Business Strategies
10.4 F. Hoffmann-La Roche Ltd
10.4.1 Quick Facts
10.4.2 Company Overview
10.4.3 Product Portfolio
10.4.4 Business Strategies
10.5 Fresenius Kabi AG
10.5.1 Quick Facts
10.5.2 Company Overview
10.5.3 Product Portfolio
10.5.4 Business Strategies
10.6 Merck & Co., Inc.
10.6.1 Quick Facts
10.6.2 Company Overview
10.6.3 Product Portfolio
10.6.4 Business Strategies
10.7 Pfizer
10.7.1 Quick Facts
10.7.2 Company Overview
10.7.3 Product Portfolio
10.7.4 Business Strategies
10.8 Takeda Pharmaceutical Company Limited
10.8.1 Quick Facts
10.8.2 Company Overview
10.8.3 Product Portfolio
10.8.4 Business Strategies
10.9 Teva Pharmaceutical Industries Ltd.
10.9.1 Quick Facts
10.9.2 Company Overview
10.9.3 Product Portfolio
10.9.4 Business Strategies
10.10 Viatris
10.10.1 Quick Facts
10.10.2 Company Overview
10.10.3 Product Portfolio
10.10.4 Business Strategies
1. Global Hodgkin Lymphoma Treatment Market Research and Analysis by Treatment Modality, 2025–2035 ($ Million)
2. Global Hodgkin Lymphoma Treatment Chemotherapy Market Research and Analysis by Region, 2025–2035 ($ Million)
3. Global Hodgkin Lymphoma Treatment Immunotherapy Market Research and Analysis by Region, 2025–2035 ($ Million)
4. Global Hodgkin Lymphoma Treatment Radiation Therapy Market Research and Analysis by Region, 2025–2035 ($ Million)
5. Global Hodgkin Lymphoma Treatment Targeted Therapy Market Research and Analysis by Region, 2025–2035 ($ Million)
6. Global Hodgkin Lymphoma Other Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
7. Global Hodgkin Lymphoma Treatment Market Research and Analysis by Drug Class 2025–2035 ($ Million)
8. Global Hodgkin Lymphoma Treatment Cytotoxic Drugs (Chemotherapy) Market Research and Analysis by Region, 2025–2035 ($ Million)
9. Global Hodgkin Lymphoma Treatment Antibody-Drug Conjugates (ADC) Market Research and Analysis by Region, 2025–2035 ($ Million)
10. Global Hodgkin Lymphoma Treatment Immune Checkpoint Inhibitors Market Research and Analysis by Region, 2025–2035 ($ Million)
11. Global Hodgkin Lymphoma Treatment Corticosteroids (supportive, minor share) Market Research and Analysis by Region, 2025–2035 ($ Million)
12. Global Hodgkin Lymphoma Treatment Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)
13. Global Hodgkin Lymphoma Treatment Intravenous (IV) Market Research and Analysis by Region, 2025–2035 ($ Million)
14. Global Hodgkin Lymphoma Treatment Oral Market Research and Analysis by Region, 2025–2035 ($ Million)
15. Global Hodgkin Lymphoma Treatment Market Research and Analysis by Distribution Channel, 2025–2035 ($ Million)
16. Global Hodgkin Lymphoma Treatment for Hospital Pharmacies Research and Analysis by Region, 2025–2035 ($ Million)
17. Global Hodgkin Lymphoma Treatment for Retail Pharmacies Research and Analysis by Region, 2025–2035 ($ Million)
18. Global Hodgkin Lymphoma Treatment for Online Pharmacies Research and Analysis by Region, 2025–2035 ($ Million)
19. Global Hodgkin Lymphoma Treatment Market Research And Analysis by Region, 2025–2035 ($ Million)
20. North America Hodgkin Lymphoma Treatment Market Research and Analysis by Country, 2025–2035 ($ Million)
21. North America Hodgkin Lymphoma Treatment Market Research and Analysis by Treatment Modality, 2025–2035 ($ Million)
22. North America Hodgkin Lymphoma Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
23. North America Hodgkin Lymphoma Treatment Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)
24. North America Hodgkin Lymphoma Treatment Market Research and Analysis by Distribution Channel, 2025–2035 ($ Million)
25. Europe Hodgkin Lymphoma Treatment Market Research and Analysis by Country, 2025–2035 ($ Million)
26. Europe Hodgkin Lymphoma Treatment Market Research and Analysis by Treatment Modality, 2025–2035 ($ Million)
27. Europe Hodgkin Lymphoma Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
28. Europe Hodgkin Lymphoma Treatment Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)
29. Europe Hodgkin Lymphoma Treatment Market Research and Analysis by Distribution Channel, 2025–2035 ($ Million)
30. Asia-Pacific Hodgkin Lymphoma Treatment Market Research and Analysis by Country, 2025–2035 ($ Million)
31. Asia-Pacific Hodgkin Lymphoma Treatment Market Research and Analysis by Treatment Modality, 2025–2035 ($ Million)
32. Asia-Pacific Hodgkin Lymphoma Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
33. Asia-Pacific Hodgkin Lymphoma Treatment Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)
34. Asia-Pacific Hodgkin Lymphoma Treatment Market Research and Analysis by Distribution Channel, 2025–2035 ($ Million)
35. Rest of the World Hodgkin Lymphoma Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)
36. Rest of the World Hodgkin Lymphoma Treatment Market Research and Analysis by Treatment Modality, 2025–2035 ($ Million)
37. Rest of the World Hodgkin Lymphoma Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
38. Rest of the World Hodgkin Lymphoma Treatment Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)
39. Rest of the World Hodgkin Lymphoma Treatment Market Research and Analysis by Distribution Channel, 2025–2035 ($ Million)
1. Global Hodgkin Lymphoma Treatment Market Share by Treatment Modality, 2025 Vs 2035 (%)
2. Global Hodgkin Lymphoma Treatment Chemotherapy Market Share by Region, 2025 Vs 2035 (%)
3. Global Hodgkin Lymphoma Treatment Immunotherapy Market Share by Region, 2025 Vs 2035 (%)
4. Global Hodgkin Lymphoma Treatment Radiation Therapy Market Share by Region, 2025 Vs 2035 (%)
5. Global Hodgkin Lymphoma Treatment Targeted Therapy Market Share by Region, 2025 Vs 2035 (%)
6. Global Hodgkin Lymphoma Treatment Other Market Share by Region, 2025 Vs 2035 (%)
7. Global Hodgkin Lymphoma Treatment Market Share by Drug Class, 2025 Vs 2035 (%)
8. Global Hodgkin Lymphoma Treatment Cytotoxic Drugs (Chemotherapy) Market Share by Region, 2025 Vs 2035 (%)
9. Global Hodgkin Lymphoma Treatment Antibody-Drug Conjugates (ADC) Market Share by Region, 2025 Vs 2035 (%)
10. Global Hodgkin Lymphoma Treatment Immune Checkpoint Inhibitors Market Share by Region, 2025 Vs 2035 (%)
11. Global Hodgkin Lymphoma Treatment Corticosteroids (supportive, minor share) Market Share by Region, 2025 Vs 2035 (%)
12. Global Hodgkin Lymphoma Treatment Market Share by Route of Administration, 2025 Vs 2035 (%)
13. Global Hodgkin Lymphoma Treatment Intravenous (IV) Share by Region, 2025 Vs 2035 (%)
14. Global Hodgkin Lymphoma Treatment Oral Share by Region, 2025 Vs 2035 (%)
15. Global Hodgkin Lymphoma Treatment Market Share by Distribution Channel, 2025 Vs 2035 (%)
16. Global Hodgkin Lymphoma Treatment for Hospital Pharmacies Share by Region, 2025 Vs 2035 (%)
17. Global Hodgkin Lymphoma Treatment for Retail Pharmacies Share by Region, 2025 Vs 2035 (%)
18. Global Hodgkin Lymphoma Treatment for Online Pharmacies Share by Region, 2025 Vs 2035 (%)
19. Global Hodgkin Lymphoma Treatment Market Share by Region, 2025 Vs 2035 (%)
20. United States Hodgkin Lymphoma Treatment Market Size, 2025–2035 ($ Million)
21. Canada Hodgkin Lymphoma Treatment Market Size, 2025–2035 ($ Million)
22. UK Hodgkin Lymphoma Treatment Market Size, 2025–2035 ($ Million)
23. France Hodgkin Lymphoma Treatment Market Size, 2025–2035 ($ Million)
24. Germany Hodgkin Lymphoma Treatment Market Size, 2025–2035 ($ Million)
25. Italy Hodgkin Lymphoma Treatment Market Size, 2025–2035 ($ Million)
26. Spain Hodgkin Lymphoma Treatment Market Size, 2025–2035 ($ Million)
27. Russia Hodgkin Lymphoma Treatment Market Size, 2025–2035 ($ Million)
28. India Hodgkin Lymphoma Treatment Market Size, 2025–2035 ($ Million)
29. China Hodgkin Lymphoma Treatment Market Size, 2025–2035 ($ Million)
30. Japan Hodgkin Lymphoma Treatment Market Size, 2025–2035 ($ Million)
31. South Korea Hodgkin Lymphoma Treatment Market Size, 2025–2035 ($ Million)
32. Australia & New Zealand Hodgkin Lymphoma Treatment Market Size, 2025–2035 ($ Million)
33. ASEAN Hodgkin Lymphoma Treatment Market Size, 2025–2035 ($ Million)
34. Rest of Asia-Pacific Hodgkin Lymphoma Treatment Market Size, 2025–2035 ($ Million)
35. Latin America Hodgkin Lymphoma Treatment Market Size, 2025–2035 ($ Million)
36. Middle East & Africa Hodgkin Lymphoma Treatment Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of users within the company
